Status:

UNKNOWN

Clinical Investigation of ENO/TEO/OTO Pacing System Under MRI Environment

Lead Sponsor:

MicroPort CRM

Conditions:

Bradycardia

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The interest of the CAPRI study is to confirm the safety and the efficacy of the ENO/TEO/OTO pacing system when used under 1.5 or 3 Tesla MRI environment and in accordance with the MRI solutions guide...

Detailed Description

The purpose of CAPRI study is to confirm the safety and the efficacy of the CE marked MR conditional pacing system composed of the ENO, TEO or OTO pacemaker with VEGA pacing lead(s). Conditions to und...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Subjects who meet all the following criteria at the time of inclusion visit may be included:
  • Already implanted in the left or right pectoral region for at least 6 weeks with:
  • ENO, TEO or OTO single chamber rate response (SR) pacemaker with a VEGA pacing lead, or
  • ENO, TEO or OTO dual chamber rate response (DR) pacemaker with two VEGA pacing leads.
  • Implanted pacing system must fulfill the following parameters:
  • Battery impedance is \< 5 Kilo Ohm (kΩ)
  • Pacing capture threshold value is ≤ 2 Volts (V) at 0.35 millisecond (ms)
  • Lead impedance value between 200Ω and 3000Ω
  • No diaphragmatic or pectoral stimulation at 5V/1ms
  • P-wave minimum sensed amplitude ≥ 1mV for patients with sinus rhythm
  • R-wave minimum sensed amplitude ≥ 4mV for patients with spontaneous conduction rhythm
  • Must agree to undergo a non clinically-indicated MRI scan without intravenous injection and without sedation;
  • Have reviewed, signed and dated informed consent.
  • Subjects who meet any of the following criteria are not eligible to be included in the study:
  • Included in another clinical study that could confound the results of this study such as studies involving intra-cardiac device;
  • Have other active or abandoned cardiac implants already implanted;
  • Have other active or passive non MR conditional devices implanted such as metallic foreign body;
  • Have a history of brain aneurysm with ferromagnetic clipping;
  • Have a planned cardiac surgery within the 3 months of inclusion;
  • Have a medical MRI examination prescription planned within the 3 months of inclusion;
  • Age less than 18 years old or under guardianship or kept in detention;
  • Known pregnancy, women breastfeeding or in childbearing age without an adequate contraceptive method ;
  • Be unavailable for the scheduled follow-up associated with this clinical study or refusal to cooperate.

Exclusion

    Key Trial Info

    Start Date :

    July 18 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    August 1 2023

    Estimated Enrollment :

    270 Patients enrolled

    Trial Details

    Trial ID

    NCT03811691

    Start Date

    July 18 2019

    End Date

    August 1 2023

    Last Update

    June 9 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    MicroPort CRM

    Clamart, Haut de Seine, France, 92140